In this open-label , randomised , multicentre trial ( HD13 ) we compared two cycles of ABVD with two cycles of the reduced-intensity regimen variants ABV ( doxorubicin , bleomycin , and vinblastine ) , AVD ( doxorubicin , vinblastine , and dacarbazine ) , and AV ( doxorubicin and vinblastine ) , in patients with newly diagnosed , histologically proven , classic or nodular , lymphocyte predominant Hodgkin 's lymphoma .